Market Closed -
Japan Exchange
02:00:00 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
4,335
JPY
|
+0.65%
|
|
+3.09%
|
-13.23%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
542,875
|
571,160
|
554,319
|
561,052
|
392,668
|
291,974
|
-
|
-
|
Enterprise Value (EV)
1 |
500,737
|
524,046
|
493,520
|
503,199
|
323,731
|
217,677
|
199,487
|
180,500
|
P/E ratio
|
33.3
x
|
33.9
x
|
26.8
x
|
22.5
x
|
17.2
x
|
10.7
x
|
10.6
x
|
9.46
x
|
Yield
|
0.87%
|
1.01%
|
1.2%
|
1.32%
|
1.96%
|
2.87%
|
3.08%
|
3.36%
|
Capitalization / Revenue
|
4.73
x
|
4.9
x
|
4.55
x
|
4.08
x
|
2.72
x
|
1.96
x
|
1.9
x
|
1.82
x
|
EV / Revenue
|
4.37
x
|
4.49
x
|
4.05
x
|
3.66
x
|
2.25
x
|
1.46
x
|
1.3
x
|
1.12
x
|
EV / EBITDA
|
20.8
x
|
20.8
x
|
16.6
x
|
16.1
x
|
9.23
x
|
5.33
x
|
4.84
x
|
4.04
x
|
EV / FCF
|
35.6
x
|
51.2
x
|
26.2
x
|
52.1
x
|
37.9
x
|
9.19
x
|
8.81
x
|
7.67
x
|
FCF Yield
|
2.81%
|
1.95%
|
3.81%
|
1.92%
|
2.64%
|
10.9%
|
11.4%
|
13%
|
Price to Book
|
4.02
x
|
3.93
x
|
3.42
x
|
3.11
x
|
2.01
x
|
1.36
x
|
1.25
x
|
1.14
x
|
Nbr of stocks (in thousands)
|
67,354
|
67,354
|
67,353
|
67,353
|
67,353
|
67,353
|
-
|
-
|
Reference price
2 |
8,060
|
8,480
|
8,230
|
8,330
|
5,830
|
4,335
|
4,335
|
4,335
|
Announcement Date
|
5/13/19
|
5/13/20
|
5/14/21
|
5/11/22
|
5/11/23
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
114,716
|
116,637
|
121,885
|
137,484
|
144,175
|
149,208
|
153,400
|
160,795
|
EBITDA
1 |
24,062
|
25,136
|
29,684
|
31,232
|
35,090
|
40,872
|
41,221
|
44,726
|
EBIT
1 |
20,644
|
21,668
|
26,134
|
32,948
|
30,049
|
35,213
|
36,027
|
40,459
|
Operating Margin
|
18%
|
18.58%
|
21.44%
|
23.96%
|
20.84%
|
23.6%
|
23.49%
|
25.16%
|
Earnings before Tax (EBT)
1 |
21,540
|
22,442
|
28,759
|
33,301
|
30,489
|
35,667
|
36,434
|
40,866
|
Net income
1 |
16,302
|
16,866
|
20,702
|
24,986
|
22,812
|
27,383
|
27,626
|
31,046
|
Net margin
|
14.21%
|
14.46%
|
16.98%
|
18.17%
|
15.82%
|
18.35%
|
18.01%
|
19.31%
|
EPS
2 |
242.0
|
250.4
|
307.4
|
371.0
|
338.7
|
404.3
|
407.8
|
458.5
|
Free Cash Flow
1 |
14,068
|
10,237
|
18,805
|
9,659
|
8,539
|
23,689
|
22,644
|
23,542
|
FCF margin
|
12.26%
|
8.78%
|
15.43%
|
7.03%
|
5.92%
|
15.88%
|
14.76%
|
14.64%
|
FCF Conversion (EBITDA)
|
58.47%
|
40.73%
|
63.35%
|
30.93%
|
24.33%
|
57.96%
|
54.93%
|
52.64%
|
FCF Conversion (Net income)
|
86.3%
|
60.7%
|
90.84%
|
38.66%
|
37.43%
|
86.51%
|
81.97%
|
75.83%
|
Dividend per Share
2 |
70.00
|
86.00
|
99.00
|
110.0
|
114.0
|
124.3
|
133.6
|
145.9
|
Announcement Date
|
5/13/19
|
5/13/20
|
5/14/21
|
5/11/22
|
5/11/23
|
-
|
-
|
-
|
Fiscal Period: March |
2020 S1
|
2020 S2
|
2021 S1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 S1
|
2026 S1
|
---|
Net sales
1 |
57,387
|
59,250
|
57,817
|
30,411
|
71,568
|
34,650
|
31,329
|
35,619
|
71,136
|
38,783
|
34,256
|
37,012
|
36,302
|
73,314
|
39,414
|
35,329
|
38,000
|
76,000
|
85,000
|
EBITDA
1 |
-
|
-
|
-
|
5,792
|
-
|
8,568
|
-293
|
-
|
-
|
10,117
|
3,424
|
-
|
-
|
-
|
10,805
|
7,228
|
-
|
-
|
-
|
EBIT
1 |
11,025
|
10,643
|
11,140
|
5,056
|
21,504
|
7,817
|
-1,022
|
10,276
|
19,161
|
8,826
|
2,062
|
11,163
|
9,715
|
20,878
|
9,572
|
4,558
|
11,000
|
20,000
|
26,500
|
Operating Margin
|
19.21%
|
17.96%
|
19.27%
|
16.63%
|
30.05%
|
22.56%
|
-3.26%
|
28.85%
|
26.94%
|
22.76%
|
6.02%
|
30.16%
|
26.76%
|
28.48%
|
24.29%
|
12.9%
|
28.95%
|
26.32%
|
31.18%
|
Earnings before Tax (EBT)
1 |
11,271
|
11,171
|
11,248
|
5,652
|
22,250
|
8,313
|
-790
|
10,514
|
19,398
|
9,024
|
2,067
|
11,440
|
9,706
|
21,146
|
9,827
|
5,152
|
11,200
|
20,200
|
26,700
|
Net income
1 |
8,291
|
8,575
|
8,073
|
4,220
|
16,561
|
6,045
|
438
|
8,249
|
15,222
|
7,452
|
138
|
8,749
|
-
|
16,176
|
7,826
|
3,486
|
8,600
|
15,500
|
20,500
|
Net margin
|
14.45%
|
14.47%
|
13.96%
|
13.88%
|
23.14%
|
17.45%
|
1.4%
|
23.16%
|
21.4%
|
19.21%
|
0.4%
|
23.64%
|
-
|
22.06%
|
19.86%
|
9.87%
|
22.63%
|
20.39%
|
24.12%
|
EPS
2 |
123.1
|
-
|
119.9
|
62.65
|
245.9
|
89.75
|
6.500
|
122.5
|
226.0
|
110.6
|
2.050
|
129.9
|
-
|
240.2
|
116.2
|
37.05
|
127.7
|
230.1
|
304.4
|
Dividend per Share
2 |
43.00
|
-
|
49.00
|
-
|
51.00
|
-
|
-
|
-
|
57.00
|
-
|
-
|
-
|
62.00
|
62.00
|
-
|
60.00
|
-
|
-
|
-
|
Announcement Date
|
11/6/19
|
5/13/20
|
11/5/20
|
11/10/21
|
11/10/21
|
2/10/22
|
5/11/22
|
8/9/22
|
11/10/22
|
2/10/23
|
5/11/23
|
8/10/23
|
11/13/23
|
11/13/23
|
2/9/24
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
42,138
|
47,114
|
60,799
|
57,853
|
68,937
|
74,297
|
92,487
|
111,474
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
14,068
|
10,237
|
18,805
|
9,659
|
8,539
|
23,689
|
22,644
|
23,542
|
ROE (net income / shareholders' equity)
|
12.5%
|
12%
|
13.5%
|
13.6%
|
12.1%
|
13.4%
|
12.5%
|
12.9%
|
ROA (Net income/ Total Assets)
|
13.2%
|
13.1%
|
14.4%
|
16%
|
9.97%
|
11.9%
|
10%
|
10.3%
|
Assets
1 |
123,724
|
129,182
|
143,910
|
156,428
|
228,696
|
230,486
|
275,086
|
302,577
|
Book Value Per Share
2 |
2,003
|
2,160
|
2,409
|
2,681
|
2,904
|
3,181
|
3,467
|
3,787
|
Cash Flow per Share
2 |
293.0
|
302.0
|
360.0
|
439.0
|
414.0
|
496.0
|
488.0
|
539.0
|
Capex
1 |
1,242
|
2,500
|
2,583
|
10,744
|
5,660
|
9,000
|
8,600
|
9,385
|
Capex / Sales
|
1.08%
|
2.14%
|
2.12%
|
7.81%
|
3.93%
|
6.03%
|
5.61%
|
5.84%
|
Announcement Date
|
5/13/19
|
5/13/20
|
5/14/21
|
5/11/22
|
5/11/23
|
-
|
-
|
-
|
Last Close Price
4,335
JPY Average target price
6,371
JPY Spread / Average Target +46.98% Consensus |
1st Jan change
|
Capi.
|
---|
| -13.23% | 1.85B | | +26.47% | 661B | | +26.74% | 566B | | -6.33% | 352B | | +19.35% | 332B | | +4.23% | 283B | | +13.43% | 231B | | +4.71% | 200B | | -9.53% | 195B | | -4.04% | 145B |
Other Pharmaceuticals
|